

Nausea/Vomiting	
ADULT	PEDIATRIC
BLS Procedures	
Maintain airway and position of comfort Administer oxygen as indicated	
ALS Standing Orders	
<p>Indications for Ondansetron:</p> <ol style="list-style-type: none"> 1. Moderate to severe nausea or vomiting. 2. Potential for airway compromise secondary to suspected/actual head injury when cervical immobilization is used. 3. Prior to MS administration <ul style="list-style-type: none"> • IV/IO access • Cardiac Monitor <ul style="list-style-type: none"> • Ondansetron <ul style="list-style-type: none"> ○ PO – 4 mg ODT <ul style="list-style-type: none"> • May repeat x 1 in 10 min ○ IV/IM/IO – 4 mg <ul style="list-style-type: none"> • May repeat x 1 in 10 min 	<p>Indications for Ondansetron:</p> <ol style="list-style-type: none"> 1. Moderate to severe nausea or vomiting. 2. Potential for airway compromise secondary to suspected/actual head injury when cervical immobilization is used. 3. Prior to MS administration <ul style="list-style-type: none"> • IV/IO access • Cardiac Monitor <p>Ages 6 months up to 5 years</p> <ul style="list-style-type: none"> • Ondansetron <ul style="list-style-type: none"> ○ PO – 2 mg ODT <ul style="list-style-type: none"> • May repeat x 1 in 10 min ○ IV/IM/IO – 0.1 mg/kg <ul style="list-style-type: none"> • Max single dose 4 mg • May repeat x 1 in 10 min <p>Ages ≥ 5 Years</p> <ul style="list-style-type: none"> • Ondansetron <ul style="list-style-type: none"> ○ PO – 4 mg ODT <ul style="list-style-type: none"> • May repeat x 1 in 10 min ○ IV/IM/IO – 0.1 mg/kg <ul style="list-style-type: none"> • Max single dose 4 mg • May repeat x 1 in 10 min
Base Hospital Orders only	
Consult with ED Physician for further treatment measures	Consult with ED Physician for further treatment measures
<ul style="list-style-type: none"> • The use of ondansetron should be avoided in patients with known congenital long QT syndrome • Use caution in administration of ondansetron for patients with electrolyte imbalances, CHF, bradyarrhythmia, or patients taking medications known to prolong the QT interval 	

Effective Date: July 1, 2023
Next Review Date: January 31, 2025

Date Revised: January 12, 2023
Last Reviewed: January 12, 2023



VCEMS Medical Director